Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Baylor Charles A. Sammons Cancer Center, Dallas, TX, United States



Survival: 12.3 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Dallas, TX
   
Hospital: Baylor Charles A. Sammons Cancer Center
   
Journal: Link
   
Date: 1/2011

Description:
Patients:
This study involved women with triple-negative metastatic breast cancer, which is type of cancer that does not have estrogen receptor (ER-), progesterone receptor (PR-), or an abundance of the human epidermal growth factor receptor 2 (HER-2). Patients were divided into 2 treatment groups. Group A had 61 patients with a median age of 56 years. Group B had 62 patients with a median age of 53 years.

Treatment:
Group A: Patients were given the chemotherapy agents gemcitabine and carboplatin, as well as the biologic therapy agent iniparib (an inhibitor of a DNA damage repair protein called PARP1, therefore leading to cancer cell death).

Group B: Patients were treated with the chemotherapy agents gemcitabine and carboplatin only.

Toxicities:
There were 5 deaths in this study (3 in group A, 2 in group B) that were reported as “fatal adverse events attributable to disease progression.” Grade 4 thrombocytopenia and neutropenia, as well as grade 3 anemia and fatigue were reported.

Results:
Group A: Median progression-free survival was 5.9 months and the median overall survival was 12.3 months.
Group B: Median progression-free survival was 3.6 months and the median overall survival was 7.7 months.

Support:
This study was supported by BiPar Sciences (owned by Sanofi Aventis), makers of iniparib.

Correspondence: Dr. Joyce O’Shaughnessy; email: joyce.oshaughnessy@usoncology.com

E-mail to a Friend Email Physician More Information